SFJ IV (Pfizer)

SFJ IV and Pfizer collaborated on the registration programme for Mylotarg® (gemtuzumab), a late-stage product for the treatment of acute myeloid leukaemia. The antibody-drug conjugate was approved for this indication in the US in 2017 and in Europe in 2018.